Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune ...

NUTLEY, N.J., Nov. 3, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research in gynecologic oncology during the International Gynecologic Cancer Society (IGCS) 2025 Annual ...

Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN Session Date and Time: December 6, 2025; 9:30 AM – 11:00 AM ...

This latest pattern emphasizes competency-based learning, focusing on conceptual understanding, analytical thinking, and ...

VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of ...

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 Phase 3 MG trial. 100% of patie ...

The REZOLVE-AD Phase 2b study enrolled 393 patients with moderate-to-severe AD who had no prior treatment with biologic or ...

Bio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry ...

The issue of attendance has become a focus for the district, which has been included in a pilot program with 11 other ...

The Central Board of Secondary Education (CBSE) has issued a fourth reminder to all affiliated schools regarding the submission of registration data for Class IX and Class XI for the academic year ...

Some 22 million Americans are set to lose health insurance subsidies by the end of the year. Who are they, and what will happen if the subsidies are allowed to expire? These subsidies, known as ...

WASHINGTON — A judge has extended the deadline for AT&T customers to file a claim to be part of a $177 million settlement reached with the telecom giant over customer data breaches discovered in 2024.